Fast Five Quiz: ERBB2 (HER2) Mutation in Non-Small Cell Lung Cancer

Maurie Markman, MD

November 23, 2021

Oncogenic mutations and amplifications in ERBB2 are detected by next-generation sequencing in 2%-4% of patients with NSCLC and are associated with constitutive HER2 activation.

Learn more about HER2 mutations in NSCLC.

1 2 3 4 5 6

Next Section

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Cite this: Maurie Markman. Fast Five Quiz: ERBB2 (HER2) Mutation in Non-Small Cell Lung Cancer - Medscape - Nov 23, 2021.

Comments

Commenting is limited to medical professionals. To comment please Log-in.

Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....

Fast Five Quiz: ERBB2 (HER2) Mutation in Non-Small Cell Lung Cancer

Tables

Authors and Disclosures

Authors and Disclosures

Author(s)

Maurie Markman, MD

Comments

Email This

Feedback